The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
What if the paradigm shifts are all gone and they offer the Holy Grail instead?
October 3, 2023
"Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to consummating the proposed acquisition and any competing offers or acquisition proposals for POINT"
Have they actually consummated?
The Sunday Times: Jeremy Hunt is to push ahead with cuts to research and development tax relief for small businesses in the budget but will retain some support for sectors such as artificial intelligence and biotechnology.
Not to be negative, but keynote by Lord Bethell... If I remember correctly his idea of a British Covid LFT manufacturer was a British assembly shop churning out millions of Chinese tests.
Knew there was someone missing. Hope all is well and you won the lottery so don't need the Avacta windfall.
We can't tell you the clinical findings but relax, it's all going super well!
My thinking is that normal commission charges won't apply. I want to buy my quota as a a small way of putting monetary support into Avacta, something that buying on the open market doesn't do. It will possibly go towards covering charges for the cash raising exercise.
Dear ,
Thank you for getting in touch.
We are currently drafting our correspondence for the Avacta Group Plc Open Offer and expect this to be sent out shortly.
This correspondence will clarify the full terms of the offer, and lay out how you can take part.
I hope this has been of assistance. If you have any other questions, please get back to me.
Kind regards
Henry Milsom
Corporate Actions
Hargreaves Lansdown
Would anyone care to have a stab at future dividends? Are we looking at a future cash cow? How much cash will they be returning to shareholders in the coming years?
Jupiter are such a miserable specimen of humanity. So are the lot who lend them the shares. Must be their way of marking World Cancer Day.
I am with you on the dividend FTC7. Does anyone have thoughts on what free cash flow might be available next year say for shareholder distributions?
I'm getting a Stateside vibe. US market potentially taking first priority in both therapeutics and diagnostics? Quiet Al still playing a blinder methinks.
Incidentally, according to the Times report today Jupiter are a long-term investor in GSK. Investing in GSK while shorting AVCT, what's all that about...
Maybe they would Prof, but that would be like selling the family silver on Ebay for ten bob.
https://www.marketwatch.com/story/glaxosmithkline-shares-soar-after-unilever-bids-for-its-consumer-healthcare-unit-11642410581?siteid=bulletrss
A sale in the £50 billion ballpark would leave management with £34 billion in cash for that stake, leaving the company with £12 billion net cash.
“In theory this war chest provides ample strategic optionality to rebuild a pipeline and invest in focus therapeutic areas, but at least initially we expect many shareholders would fear a large acquisition and the risk of inferior returns,” said the analyst. Jefferies rates GlaxoSmithKline a buy.
So let's say £5B free cash to buy AVCT and £5Bn to have a crack at all the shots at goal they bring with them?
"GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of £50 billion comprising £41.7 billion in cash and £8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%.
GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects."
Glaxo up 5% to a year high above £17 this morning.
I wonder what GSK will do with £35B plus...
(I've been thinking of saying that for a long time, but you beat me to it!)
Quite agree sleepydave. Al is playing a blinder.
Point Biopharma, after a spell in the doldrums, are currently up 9% on the day. Is this an omen... or do they know something we don't know?
What do we know about the Surescreen test? Are they a reagent developer or are they actually a smokescreen for more Chinese mediocrity? I'm sure I have read comparative test results for their LFT and it didn't exactly set the heather on fire.
What about Randox, how British are their tests? I have a leaflet from them and it says results for antigen test in 1 hour. However on their website it shows a video of how to use their antigen test and the kit is quite clearly our old China... Flowflex. Again, no heather was harmed that I could see...